Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU636255B2 - Use of a topical formulation for the treatment of viral infections and neoplastic disorders - Google Patents
[go: Go Back, main page]

AU636255B2 - Use of a topical formulation for the treatment of viral infections and neoplastic disorders - Google Patents

Use of a topical formulation for the treatment of viral infections and neoplastic disorders Download PDF

Info

Publication number
AU636255B2
AU636255B2 AU87040/91A AU8704091A AU636255B2 AU 636255 B2 AU636255 B2 AU 636255B2 AU 87040/91 A AU87040/91 A AU 87040/91A AU 8704091 A AU8704091 A AU 8704091A AU 636255 B2 AU636255 B2 AU 636255B2
Authority
AU
Australia
Prior art keywords
drug
compound
viral
concentration
polysulphated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU87040/91A
Other versions
AU8704091A (en
Inventor
David Cullis-Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arthropharm Pty Ltd
Original Assignee
Arthropharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthropharm Pty Ltd filed Critical Arthropharm Pty Ltd
Priority to AU87040/91A priority Critical patent/AU636255B2/en
Publication of AU8704091A publication Critical patent/AU8704091A/en
Application granted granted Critical
Publication of AU636255B2 publication Critical patent/AU636255B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

636255 1-
AUSTRALIA
Patents Act 1990 p..
jSeg
S
*3* eel' e, a.
SP.
is U C
C.
ARTHROPHARM PTY LTD
C
*S@*e
S
C.
S p
S
COMPLETE SPECIFICATION Invention Title: Use of a Topical Formulation for the Treatment of Viral Inwfections and Neoplastic Disorders The invention is described in the following statement: 2 Field of the Invention This invention relates to therapeutic compositions for the topical treatment of viral conditions and neoplastic disorders, in particular to a composition in topical form comprising an anti-viral or an anti-neoplastic drug in combination with a potentiating drug which is an anti-inflammatory or an anti-oxidant drug.
Background to the Invention Topical drug treatments of viral conditions such as herpes simplex and neoplastic disorders such as carcinoma of the skin have been used for many years with only a moderate degree of success.
se* A number of drugs which demonstrate anti-viral activity in-vitro and when used systemically, surprisingly 15 do not show efficacy when used topically. Examples of O* such drugs are sulphated polysaccharides as described by Parish et al, Inst. J. Cancer, 511-518 (1987), particularly dextran sulphate, pentosan polysulphate, fucoidan and carageenans Baba et al, Antimicrobial Agents 20 and Chemotherapy, 12 1742-1748 (1988) specifically disclose that these compounds were found when tested 0 in-vitro to be potent inhibitors for herpes simplex virus, human cytomegalovirus, visicular stomatitis virus, Sindbis virus and human immuno-deficiency virus. They were also found to be moderately inhibitory to vaccinia virus but not inhibitory to adeno virus, coxsackie virus, polio virus, para-influenza virus and reo virus.
Sodium pentosan polysulphate (SP54) has also been shown by Raff et al, Munch. Med. Wschr., .11, 23, 817-818 (1977) to have potent anti-viral activity both in-vitro and when given intramuscularly in the treatment of herpes zoster.
Other drugs falling within the scope of this group which exhibit in-vitro and systemic anti-viral activity include foscarnet, suramin, polysulphated polysaccharides, 3 polysulphated polymers, purine nucleoside analogues and derivatives thereof.
Elsewhere, in US4710493 (Landsberger) are disclosed compositions comprising in combination a glycosoaminoglycan polysulphate (excluding heparin) and a cytotoxic drug.
The known serious side effects of the cytotoxic drug were found to be considerably reduced by this combination.
Summary of the Invention The present inventor has found that although the aforementioned drugs are essentially ineffective in the o" *topical treatment of viral conditions and neoplastic :disorders, surprisingly the combination of one of these see drugs with an anti-inflammatory or anti-oxidant drug *on results in the potentiation of the first mentioned drug, 15 thereby providing an effective topical treatment for these e conditions and disorders.
This finding is particularly surprising given that a topical formulation comprising a pentosan polysulphate in combination with ethylene glycol monosalicylate ester has 20 been sold for a number of years for the treatment of musculoskeletal disorders.
It is still further surprising given that when either of the drugs are used separately in topical form, they are essentially inactive.
25 Accordingly, the present invention consists in a method for the topical treatment of viral conditions or neoplastic disorders comprising applying an effective amount of a composition which includes a first compound selected from the group consisting of foscarnet, suramin, sulphated polysaccharides, polysulphated polysaccharides, polysulphated polymers, purine nucleoside analogues and derivatives thereof, and an amount of an anti-inflammatory or anti-oxidant.drug sufficient to potentiate the activity of the first compound, to an area of the skin or mucous membranes affected by a viral condition or neoplastic 4 disorder.
Description of the Invention It is preferred that the first compound is selected from the group consisting of foscarnet, suramin, sulphated polysaccharides such as heparin and polysulphated saccharides such as dextran polysulphate, pentosan polysulphate, manose polysulphate, carageenan and fucoidan and monovalent and polyvalent salts and complexes thereof. Preferred anti-inflammatory drugs are selected from non-steroidal and steroidal groups of drugs with the anti-oxidant drug being selected from carotenoids, 0ege vitamin E, vitamin A, retinoic acid and retinol and derivatives thereof.
Amongst the non-steroidal anti-inflammatory group of 15 drugs that may be used are salicylate derivatives and compounds such as diclofenac, naproxen and bufexamac.
More preferably the anti-viral and/or anti-neoplastic compound is a polysulphated polysaccharide in the form of monovalent or polyvalent salts and complexes, of molecular 20 weight between about 1,000 and 30,000 Daltons and in a concentration of from 0.01 to 20 weight percent. These monovi 'ent or polyvalent salts and complexes are disclosed in the present applicant's patent application W088/07060, the contents of which are incorporateed herein. Magnesium complexes and zinc complexes of polysulphated polysaccharide are preferred as both magnesium and zinc are known to assist in wound healing.
Generally in the compositions of the invention, the anti-inflammatory drug or anti-oxidant drug will be incorporated in an amount of about 0.01 to about 50 weight percent.
Most preferably the anti-viral and anti-neoplastic compound is pentosan polysulphate of a molecular weight about 6,000 Daltons in a concentration of about 0.5 weight percent whilst the anti-inflammatory drug is 5 triethanolamine salicylate in a concentration of about weight percent or bufexamac in a concentration of about 1 weight Particularly preferred is the zinc complex of pentosan polysulphate in combination with bufexamac.
The compositions of the invention will be formulated using pharmaceutical bases suitable to the site of application and may include dosage forms such as creams, ointments, lotions and the like. A person of skill in this art could readily formulate suitable such *o compositions.
In order to better understand and appreciate the o nature of this invention, a number of examples will now be *o described.
15 Example 1 of zinc pentosan polysulphate and 10ml of triethanolamine salicylate was mixed with 90ml of sorbolene cream.
This formulation was applied topically to a patient 0 20 with the following clinical history. Extensive superficial herpes errosions to the skin resistant to conventional therapy. A formulation containing zinc pentosan polysulphate was applied with no effect. Viral culture indicated that the virus was resistant to a number of agents but was sensitive to foscarnet, which was administered for 2 weeks by intravenous infusion. One week after the cessation of the foscarnet therapy the lesions re-occurred. The lesion was then treated with the mixture of zinc pentosan polysulphate and triethanolamine salicylate in a cream base. Two days after treating the lesions with the mixture the lesions healed and have remained absent for a period of 3 months.
Example 2 Zinc pentosan polysulphate at a concentration of and sodium pentosan polysulphate at a concentration of 4% 6 was compared to 0.5% zinc pentosan polysulphate mixed with triethanolamine salicylate.
Five patients were treated with each formulation twice daily on the lesions. Only the group receiving the zinc pentosan polysulphate mixed with triethanolamine salicylate, showed alteration of the course of the lesions, and were essentially asymptomatic at 48 hours after start of treatment, Example 3 Four cases of chronic herpes simplex of five or more c* years duration of the lip were treated with sodium pentosan polysulphate combined with ethylene glycol siea monosalicylate ester in a cream base. All cases resolved within 2-5 days and no further outbreaks in that 15 area of skin have occurred over the proceeding 12 months Example 4 Early skin carcinoma characterised by roughening of the skin on the skull of a 60 year old male, which had previously been treated with crysurgery, were treated 20 twice daily with a 0.5% pentosan polysulphate and ethylene glycol monosalicylate ester in a cream base. The lesions resolved and have remained clear for 12 months.
Example 10 cases of herpes simplex were treated with a cream comprising 1 weight percent bufexamac and 0.5 weight percent zinc pentosan polysulphate.
The results achieved were comparable to those achieved in Example 2 in which triethanolamine salicylate was used in place of bufexamac 1%.
It will be seen from these Examples that this invention provides effective treatment of a number of topical viral and neoplastic disorders. The treatments may be readily administered given that the compositions used for the treatment are in dosage forms such as creams, ointments and lotions.
7 Whilst this invention has been described with reference to the Examples and certain preferred embodiments, it will be appreciated by those skilled in the art that numerous variations and modifications are possible without departing from the spirit or scope thereof as broadly described.
some see: memo noo.
too*
S
emae *5 *6 *5 e Se
S
a a, S

Claims (11)

1. A method for the topical treatment of viral conditions or neoplastic disorders comprising applying an effective amount of a composition which includes a first compound selected from the group consisting of foscarnet, suramin, sulphated polysaccharides, polysulphated polysaccharides, polysulphated polymers, purine nucleoside analogues and derivatives thereof and an amount of an anti-inflammatory or anti-oxidant drug sufficient to potentiate the activity of the first compound, to an area of the skin or mucous membranes affected by a viral condition or neoplastic disorder.
2. A method as claimed in claim 1 wherein the first *ass compound is selected from the group consisting of a 15 foscarnet, suramin, sulphated polysaccharides, polysulphated polysaccharides, carageenan and fucoidan, including their monovalent and polyvalent salts and complexes.
3. A method as in claim 1 or claim 2 wherein the 0 20 anti-inflammatory drug is selected from non-steroidal and a* steroidal drugs.
4. A method as in claim 3 wherein the anti-oxidant drug is selected from the group consisting of carotenoids, vitamin E, vitamin A, retinol and retinoic acid and 25 derivatives thereof.
5. A method as in claim 4 wherein the first compound is a polysulphated polysaccharide selected from the group consisting of dextran polysulphate, pentosan polysulphate and manose polysulphate.
6. A method as in claim 5 wherein the polysulphated polysaccharide is in the form of monovalent or polyvalent salts and complexes of molecular weight between about 1,000 and 30,000 Daltons and is in a concentration of from 0.01 to 20 weight percent. 9
7. A method as in claim 6 wherein the anti-inflammatory drug is selected from the group consisting of diclofenac, naproxen, salicylate derivatives and bufexamac, in a concentration of from 0.01 50 weight percent.
8. A method as in claim 7 wherein the first compound is the zinc or magnesium complex of pentosan polysulphate of molecular weight about 6,000 Daltons in a concentration of about 0.5 weight percent and the anti-inflammatory drug is triethanolamine salicylate in a concentration of about weight or bufexamac in a concentration of about 1 weight
9. A method as in claim 8 wherein the first compound is the zinc complex of pentosan polysulphate and the *anti-inflammatory drug is bufexamac. 15
10. A method as in claim 9 wherein the viral condition is herpes simplex.
11. A method as in claim 9 wherein the neoplastic disorder is skin carcinoma. DATED this 5't day of November 1991 ARTHROPHARM PTY LTD Patent Attorneys for the Applicant: F.B. RICE CO. ABSTRACT A method for the topical treatment of viral infections and neoplastic disorders of the skin and mucous membranes is disclosed. This method uses a topical preparation comprising an anti-viral or an anti-neoplastic drug in combination with a potentiating drug which is an anti-inflammatory or an anti-oxidant drug. A preferred preparation includes zinc pentosan polysulphate in combination with bufexamac. See •0O S a 0e oi
AU87040/91A 1990-11-05 1991-11-05 Use of a topical formulation for the treatment of viral infections and neoplastic disorders Ceased AU636255B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU87040/91A AU636255B2 (en) 1990-11-05 1991-11-05 Use of a topical formulation for the treatment of viral infections and neoplastic disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK3174 1990-11-05
AUPK317490 1990-11-05
AU87040/91A AU636255B2 (en) 1990-11-05 1991-11-05 Use of a topical formulation for the treatment of viral infections and neoplastic disorders

Publications (2)

Publication Number Publication Date
AU8704091A AU8704091A (en) 1992-05-07
AU636255B2 true AU636255B2 (en) 1993-04-22

Family

ID=25640779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87040/91A Ceased AU636255B2 (en) 1990-11-05 1991-11-05 Use of a topical formulation for the treatment of viral infections and neoplastic disorders

Country Status (1)

Country Link
AU (1) AU636255B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337324B1 (en) 1995-02-06 2002-01-08 Medivir, Ab Pharmaceutical combination
EP1487432A4 (en) * 2002-03-26 2008-06-25 Eastern Virginia Med School SURAMINA AND ITS DERIVATIVES AS MICROBICIDE AND CONTRACEPTIVE

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337324B1 (en) 1995-02-06 2002-01-08 Medivir, Ab Pharmaceutical combination
USRE39264E1 (en) * 1995-02-06 2006-09-05 Medivir Ab Pharmaceutical combination
EP1487432A4 (en) * 2002-03-26 2008-06-25 Eastern Virginia Med School SURAMINA AND ITS DERIVATIVES AS MICROBICIDE AND CONTRACEPTIVE
US7476693B2 (en) 2002-03-26 2009-01-13 Eastern Virginia Medical School Suramin and derivatives thereof as topical microbicide and contraceptive

Also Published As

Publication number Publication date
AU8704091A (en) 1992-05-07

Similar Documents

Publication Publication Date Title
US5514667A (en) Method for topical treatment of herpes infections
US6399093B1 (en) Method and composition to treat musculoskeletal disorders
US6524623B1 (en) Therapeutic compositions and methods of use thereof
US6656925B2 (en) Composition and method of treating arthritis
EP1165097B1 (en) A pharmaceutical composition of complex carbohydrates and their use
US9387227B2 (en) Method for treatment of sores and lesions of the skin
US5977087A (en) Topical preparation for treatment of aphthous ulcers and other lesions
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
WO2019155389A1 (en) An aqueous mucoadhesive and bioadhesive composition for the treatment
AU2002312416A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
KR20110074513A (en) Topical treatment of skin infections
Partridge et al. Topical carbenoxolone sodium in the management of herpes simplex infection
AU2008203101A1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
CA2175282A1 (en) Use of forms of hyaluronic acid (ha) for the treatment of cancer
AU636255B2 (en) Use of a topical formulation for the treatment of viral infections and neoplastic disorders
EP2149378B1 (en) Topical formulations for the symptomatic treatment of musculoskeletal disorders
US20060024241A1 (en) Vitamin B12 compositions
BE1019216A3 (en) ADHESIVE PLASTER FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS.
US20070178141A1 (en) Vitamin B12 compositions
CN115209954A (en) Composition for treating respiratory disorders
Shastry et al. Topical drug delivery: An essential aid in the management of oral diseases
Van der Rhee et al. Treatment of psoriasis vulgaris with a low-dosage Ro 10-9359 (Tigason) orally combined with corticosteroids topically
WO2024261713A1 (en) Topical regimen for treating cold sores
RU2147440C1 (en) Analgetic and anti-itching agent
US20030114534A1 (en) Pharmaceutical preparation for apthous ulcers